HR and breast carcinoma: Breast cancer subtypes at MBC diagnosis included HR+/HER2- (n = 184, 36.3%), HR+/HER2+ (n = 96, 18.9%), HR-negative (HR-)/HER2+ (n = 101, 19.9%), and TNBC (n = 126, 24.9%).